IPP Bureau
LifeMine Therapeutics and GSK enter drug discovery and development alliance
By IPP Bureau - March 24, 2022
The collaboration will utilize Avatar-Rx, LifeMine’s proprietary genomically-enabled drug discovery platform to access evolutionarily derived lead small molecules
Johnson & Johnson India launches ‘Be The Change For TB’ initiative
By IPP Bureau - March 24, 2022
#BeTheChangeForTB is a public awareness initiative under the Corporate TB Pledge and aims to create a cadre of Youth Changemakers who can act as catalysts of change to help eliminate TB from India
Lupin receives approval from USFDA for Sildenafil for Oral Suspension
By IPP Bureau - March 24, 2022
The product will be manufactured at Lupin’s facility in Goa, India
USFDA approves Novartis Pluvicto to treat prostrate cancer
By IPP Bureau - March 24, 2022
USFDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions
MedisimVR raises Rs 3.5 cr. in Pre-Series A round led by Inflection Point Ventures
By IPP Bureau - March 24, 2022
MedisimVR is a VR based medical education platform for doctors, nurses & allied health professionals. It aims to make comprehensive Virtual Reality medical simulation more accessible and affordable
Carestream Health India launch Lux 35 detector
By IPP Bureau - March 24, 2022
The new glass-free detector has improved durability, is more reliable, and has an improved rugged design to sustain in a high workload environment
.jpg "Kiran Mazumdar-Shaw elected as the Fellow of Royal Society of Edinburgh")
Kiran Mazumdar-Shaw elected as the Fellow of Royal Society of Edinburgh
By IPP Bureau - March 24, 2022
Kiran will be joining RSE's current Fellowship of around 1,700 Fellows who are recognized as being some of the greatest thinkers, researchers and practitioners working in or with Scotland
Pfizer granted USFDA Breakthrough Therapy Designation for RSV vaccine candidate
By IPP Bureau - March 24, 2022
The FDA decision is primarily informed by the positive results of a proof-of-concept, Phase 2a study evaluating the safety, immunogenicity, and efficacy of a single dose of 120µg RSVpreF in a human viral challenge model in healthy adults 18 to 50 years of age
Insilico Medicine and EQRx to jointly advance AI-driven drug discovery
By IPP Bureau - March 24, 2022
The collaboration leverages Insilico's end-to-end AI-driven Pharma.AI platform to discover novel small molecule drug candidates for multiple targets, along with EQRx's innovative business model to accelerate drug development and patient access to novel medicines at affordable prices
Totus Medicines partners with Mila on a mission to treat the untreatable
By IPP Bureau - March 24, 2022
Organizations to combine expertise to further develop AI/ML-powered drug design platform, delivering precise, effective, and life-changing medicines at scale
Covovax for teens get DCGI nod
By IPP Bureau - March 23, 2022
It is the fourth vaccine to get the nod for 12 years and older after Biological E’s Corbevax, Bharat Biotech’s Covaxin and Zydus Lifesciences Zy-CoV-D
Akron BioProducts and Vor Bio to develop and cGMP manufacture of nucleases
By IPP Bureau - March 23, 2022
This collaboration strengthens Akron’s portfolio of off-the-shelf gene-editing technologies while broadening Vor Bio’s collection of nucleases to engineer gene-modified cell therapies
Orgenics to conduct toxicology study on its intransal COVID-19 vaccine candidate
By IPP Bureau - March 23, 2022
Data to establish the safety profile and human dose of vaccine candidate
Paige launches AI software to detect breast cancer metastases in lymph nodes
By IPP Bureau - March 23, 2022
Paige Breast Lymph Node designed to enhance diagnostic accuracy and confidence detecting breast cancer metastases of any size in lymph node tissue
Study shows green Mediterranean diet modifies bacterial population in gut
By IPP Bureau - March 23, 2022
The study was published recently in Genome Medicine, a leading international journal focused on translational, genomic-based medicine
